Insider Buying: NextCure (NASDAQ:NXTC) Major Shareholder Acquires $179,336.82 in Stock

NextCure, Inc. (NASDAQ:NXTC) major shareholder Adar1 Capital Management, Llc bought 36,303 shares of the stock in a transaction that occurred on Friday, July 31st. The stock was bought at an average price of $4.94 per share, with a total value of $179,336.82. Following the completion of the acquisition, the insider owned 722,419 shares of the company’s stock, valued at $3,568,749.86. This trade represents a 5.29% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Major shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.

Adar1 Capital Management, Llc also recently made the following trade(s):

• On Thursday, July 30th, Adar1 Capital Management, Llc purchased 292,850 shares of NextCure stock. The shares were bought at an average cost of $4.93 per share, with a total value of $1,443,750.50.
• On Wednesday, July 29th, Adar1 Capital Management, Llc purchased 3,410 shares of NextCure stock. The stock was bought at an average price of $5.00 per share, for a total transaction of $17,050.00.
• On Tuesday, July 28th, Adar1 Capital Management, Llc acquired 6,400 shares of NextCure stock. The shares were bought at an average cost of $4.95 per share, with a total value of $31,680.00.
• On Monday, July 27th, Adar1 Capital Management, Llc acquired 7,798 shares of NextCure stock. The shares were purchased at an average price of $5.00 per share, with a total value of $38,990.00.

NextCure Trading Down 9.2%

Shares of NXTC opened at $5.25 on Thursday. The firm has a market capitalization of $18.95 million, a P/E ratio of -0.31 and a beta of 1.27. The stock’s fifty day simple moving average is $3.38 and its 200 day simple moving average is $8.48. NextCure, Inc. has a twelve month low of $1.55 and a twelve month high of $15.74.

NextCure (NASDAQ:NXTC) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($1.87) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.10) by $0.23. Sell-side analysts predict that NextCure, Inc. will post -7.89 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on NXTC. HC Wainwright reiterated a “buy” rating and set a $20.00 price objective on shares of NextCure in a research note on Wednesday, July 15th. Weiss Ratings downgraded shares of NextCure from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, July 7th. Wall Street Zen lowered shares of NextCure from a “hold” rating to a “sell” rating in a report on Saturday, July 18th. Finally, Zacks Research raised shares of NextCure from a “strong sell” rating to a “hold” rating in a research report on Thursday, June 11th. Two research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $19.00.

Hedge Funds Weigh In On NextCure

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Marshall Wace LLP acquired a new stake in NextCure in the fourth quarter valued at approximately $160,000. Millennium Management LLC acquired a new position in shares of NextCure during the fourth quarter worth $185,000. Geode Capital Management LLC boosted its stake in shares of NextCure by 18.6% in the fourth quarter. Geode Capital Management LLC now owns 23,157 shares of the company’s stock valued at $329,000 after purchasing an additional 3,636 shares during the period. Cable Car Capital LP boosted its stake in shares of NextCure by 13.1% in the second quarter. Cable Car Capital LP now owns 758,141 shares of the company’s stock valued at $349,000 after purchasing an additional 88,040 shares during the period. Finally, Renaissance Technologies LLC grew its holdings in NextCure by 18.7% during the 4th quarter. Renaissance Technologies LLC now owns 33,634 shares of the company’s stock valued at $477,000 after purchasing an additional 5,300 shares in the last quarter. Hedge funds and other institutional investors own 42.65% of the company’s stock.

NextCure Company Profile

NextCure, Inc is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel immune modulators for the treatment of cancer and inflammatory diseases. Leveraging its proprietary Therapeutic Discovery Engine (TDE™), the company aims to identify, validate and optimize new targets in the immune response pathway. NextCure’s research platform integrates large‐scale proteomics and functional genomics to accelerate the progression of promising therapeutic candidates from early discovery through clinical development.

The company’s pipeline includes multiple product candidates in various stages of preclinical and clinical evaluation.